|
|
||||||||
European Journal of Cardio-Thoracic Surgery, Vol 3, 305-311, Copyright © 1989 by European Association for Cardio-thoracic Surgery
N al-Khaja, A Belboul, S Larsson and D Roberts
The Carpentier-Edwards porcine valve bioprosthesis was implanted in 299
patients (325 prostheses) from April 1976 to April 1982. The series
consisted of aortic valve replacement in 150 patients, mitral valve
replacement in 120, multiple valve replacement in 26, pulmonary valve
replacement in 2 and tricuspid valve replacement in 1 patient. The
postoperative follow-up was 100% complete. The total accumulated follow- up
was 1956 patient-years. The early mortality was 6.4% (20 patients) and the
late mortality was 22% (62 patients). Valve-related mortality was seen in 8
patients (2.7%): 1 paravalvular leak during the 1st 30 postoperative days
and 7 late mortalities (1 endocarditis, 2 paravalvular leaks and 4 deaths
during reoperation). Three operative deaths (1.5%) occurred. The overall
patient survival including operative deaths was 78.5% +/- 5% at 5 years and
66% +/- 4% at 10 years. The incidence of the different complications were:
thromboembolism in 5 patients (1.7%) with a risk of 0.3%, haemorrhage in 1
(0.3%) with a risk of 0.05%, endocarditis in 2 (0.7%) with a risk of 0.1%,
and paravalvular leak in 11 patients (3.7%) with a risk of 0.6%. There was
a high incidence of tissue failure during the last 6 years which occurred
in 54 patients (18%) with a risk of 2.7%. Sixty- seven patients (22.5%)
were reoperated upon during the 11 years with an annual risk of 3.4% and
the main cause of reoperation was primary tissue failure. The
Carpentier-Edwards biological valve was shown to be efficient during the
first 5 years of implantation after which the incidence of tissue failure
increased.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Eleven years' experience with Carpentier-Edwards biological valves in relation to survival and complications
Department of Thoracic and Cardiovascular Surgery, Sahlgren's Hospital, University of Gothenburg, Sweden.
This article has been cited by other articles:
![]() |
N. D. Desai and G. T. Christakis Bioprosthetic Aortic Valve Replacement: Stented Pericardial and Porcine Valves Card. Surg. Adult, January 1, 2008; 3(2008): 857 - 894. [Full Text] |
||||
![]() |
A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 573 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Gherli, A. Colli, C. Fragnito, F. Nicolini, B. Borrello, S. Saccani, R. D'Amico, and C. Beghi Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study Circulation, August 3, 2004; 110(5): 496 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Desai and G. T. Christakis Stented Mechanical/Bioprosthetic Aortic Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856. [Full Text] |
||||
![]() |
D. D. Glower, W. D. White, A. C. Hatton, L. R. Smith, W. G. Young, W. G. Wolfe, and J. E. Lowe Determinants of reoperation after 960 valve replacements with Carpentier-Edwards prostheses J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 381 - 393. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |